Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 24.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 454,407 shares of the company's stock after buying an additional 89,235 shares during the period. Canada Pension Plan Investment Board owned about 0.12% of Moderna worth $18,894,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MRNA. abrdn plc lifted its position in Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock valued at $12,842,000 after acquiring an additional 69,360 shares during the last quarter. Spire Wealth Management grew its holdings in Moderna by 2,150.4% during the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company's stock worth $966,000 after acquiring an additional 22,192 shares during the period. Proficio Capital Partners LLC boosted its holdings in Moderna by 4,418.9% during the fourth quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock worth $6,127,000 after buying an additional 144,099 shares in the last quarter. South Dakota Investment Council raised its holdings in Moderna by 4.0% during the fourth quarter. South Dakota Investment Council now owns 299,399 shares of the company's stock worth $12,449,000 after purchasing an additional 11,500 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock valued at $300,219,000 after buying an additional 171,774 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of analyst reports. Berenberg Bank boosted their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Bank of America decreased their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and dropped their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Morgan Stanley decreased their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $58.70.

Moderna Stock Up 3.0 %

Shares of MRNA traded up $0.78 during midday trading on Wednesday, reaching $26.52. 7,994,064 shares of the stock were exchanged, compared to its average volume of 7,318,093. The company has a market cap of $10.25 billion, a price-to-earnings ratio of -2.86 and a beta of 2.23. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $170.47. The firm has a 50 day simple moving average of $30.48 and a 200-day simple moving average of $39.07.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.